JP2017509694A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017509694A5 JP2017509694A5 JP2016568146A JP2016568146A JP2017509694A5 JP 2017509694 A5 JP2017509694 A5 JP 2017509694A5 JP 2016568146 A JP2016568146 A JP 2016568146A JP 2016568146 A JP2016568146 A JP 2016568146A JP 2017509694 A5 JP2017509694 A5 JP 2017509694A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutical composition
- ring
- disease
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 26
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 150000001875 compounds Chemical class 0.000 claims 19
- 239000000556 agonist Substances 0.000 claims 15
- 229920006395 saturated elastomer Polymers 0.000 claims 14
- 210000001519 tissue Anatomy 0.000 claims 14
- 125000003545 alkoxy group Chemical group 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- 229910052757 nitrogen Inorganic materials 0.000 claims 12
- 206010016654 Fibrosis Diseases 0.000 claims 11
- 125000003118 aryl group Chemical group 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 11
- 230000004761 fibrosis Effects 0.000 claims 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 10
- 230000000750 progressive effect Effects 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 9
- 125000005842 heteroatom Chemical group 0.000 claims 9
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 8
- 125000002947 alkylene group Chemical group 0.000 claims 8
- 125000004432 carbon atom Chemical group C* 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 230000000893 fibroproliferative effect Effects 0.000 claims 7
- 210000000056 organ Anatomy 0.000 claims 7
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 7
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 6
- 229910052801 chlorine Inorganic materials 0.000 claims 6
- 229910052731 fluorine Inorganic materials 0.000 claims 6
- 210000003734 kidney Anatomy 0.000 claims 6
- 210000004072 lung Anatomy 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 208000017169 kidney disease Diseases 0.000 claims 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 5
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000004193 piperazinyl group Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 claims 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 3
- 208000019693 Lung disease Diseases 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
- 210000002744 extracellular matrix Anatomy 0.000 claims 3
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- -1 methyl halogen Chemical class 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 238000007634 remodeling Methods 0.000 claims 3
- 210000005084 renal tissue Anatomy 0.000 claims 3
- ZYXWYDDFNXBTFO-UHFFFAOYSA-N tetrazolidine Chemical compound C1NNNN1 ZYXWYDDFNXBTFO-UHFFFAOYSA-N 0.000 claims 3
- FTTATHOUSOIFOQ-UHFFFAOYSA-N 1,2,3,4,6,7,8,8a-octahydropyrrolo[1,2-a]pyrazine Chemical compound C1NCCN2CCCC21 FTTATHOUSOIFOQ-UHFFFAOYSA-N 0.000 claims 2
- FEQOLYDPQKHFTD-UHFFFAOYSA-N 1-(2,2-diphenyloxolan-3-yl)-n,n-dimethylmethanamine;hydrochloride Chemical compound Cl.CN(C)CC1CCOC1(C=1C=CC=CC=1)C1=CC=CC=C1 FEQOLYDPQKHFTD-UHFFFAOYSA-N 0.000 claims 2
- UVSWWUWQVAQPJR-UHFFFAOYSA-N 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine Chemical compound C1=C(OC)C(OC)=CC=C1CCN1CCN(CCCC=2C=CC=CC=2)CC1 UVSWWUWQVAQPJR-UHFFFAOYSA-N 0.000 claims 2
- CFJMRBQWBDQYMK-UHFFFAOYSA-N 1-phenyl-1-cyclopentanecarboxylic acid 2-[2-(diethylamino)ethoxy]ethyl ester Chemical compound C=1C=CC=CC=1C1(C(=O)OCCOCCN(CC)CC)CCCC1 CFJMRBQWBDQYMK-UHFFFAOYSA-N 0.000 claims 2
- QXXHHHWXFHPNOS-UHFFFAOYSA-M 1-phenylcyclohexane-1-carboxylate Chemical compound C=1C=CC=CC=1C1(C(=O)[O-])CCCCC1 QXXHHHWXFHPNOS-UHFFFAOYSA-M 0.000 claims 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 2
- 239000005977 Ethylene Substances 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- IGVDQXLOMXGWKN-CYBMUJFWSA-N bd1031 Chemical compound C1=C(Cl)C(Cl)=CC=C1CCN1C[C@H]2CCCN2CC1 IGVDQXLOMXGWKN-CYBMUJFWSA-N 0.000 claims 2
- IKFDBDJFYBCATB-UHFFFAOYSA-N bd1052 Chemical compound C1=C(Cl)C(Cl)=CC=C1CCN(CC=C)CCN1CCCC1 IKFDBDJFYBCATB-UHFFFAOYSA-N 0.000 claims 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000003176 fibrotic effect Effects 0.000 claims 2
- 229960004038 fluvoxamine Drugs 0.000 claims 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 229910052740 iodine Inorganic materials 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000002577 pseudohalo group Chemical group 0.000 claims 2
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims 1
- RQHKZUBCUZVZEF-UHFFFAOYSA-N 1-phenyl-1-cyclohexanecarboxylic acid 2-(4-morpholinyl)ethyl ester Chemical compound C1CCCCC1(C=1C=CC=CC=1)C(=O)OCCN1CCOCC1 RQHKZUBCUZVZEF-UHFFFAOYSA-N 0.000 claims 1
- HELCSESNNDZLFM-UHFFFAOYSA-N 4-iodo-N-[1-(phenylmethyl)-4-piperidinyl]benzamide Chemical compound C1=CC(I)=CC=C1C(=O)NC1CCN(CC=2C=CC=CC=2)CC1 HELCSESNNDZLFM-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- LOLWCQYYVMUPNN-UHFFFAOYSA-N C(C1=CC=CC=C1)N1CCN(CC1)NC(C1=CC=C(C=C1)I)=O Chemical compound C(C1=CC=CC=C1)N1CCN(CC1)NC(C1=CC=C(C=C1)I)=O LOLWCQYYVMUPNN-UHFFFAOYSA-N 0.000 claims 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 claims 1
- 208000023783 Genitourinary tract disease Diseases 0.000 claims 1
- WNZBBTJFOIOEMP-UHFFFAOYSA-N Hydroxyhaloperidol Chemical compound C=1C=C(F)C=CC=1C(O)CCCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 WNZBBTJFOIOEMP-UHFFFAOYSA-N 0.000 claims 1
- 208000012659 Joint disease Diseases 0.000 claims 1
- 208000019428 Ligament disease Diseases 0.000 claims 1
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 claims 1
- 208000016222 Pancreatic disease Diseases 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 125000004367 cycloalkylaryl group Chemical group 0.000 claims 1
- 150000001983 dialkylethers Chemical class 0.000 claims 1
- 210000002249 digestive system Anatomy 0.000 claims 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 229960002464 fluoxetine Drugs 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 229960003878 haloperidol Drugs 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 208000028774 intestinal disease Diseases 0.000 claims 1
- 210000003041 ligament Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000002346 musculoskeletal system Anatomy 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 210000004923 pancreatic tissue Anatomy 0.000 claims 1
- 229960003436 pentoxyverine Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000003053 piperidines Chemical class 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 210000004994 reproductive system Anatomy 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 229960002073 sertraline Drugs 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14462004 | 2014-02-07 | ||
| EP14462004.4 | 2014-02-07 | ||
| PCT/HU2015/000014 WO2015118365A1 (en) | 2014-02-07 | 2015-02-09 | Novel use of sigma-1 receptor agonist compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017509694A JP2017509694A (ja) | 2017-04-06 |
| JP2017509694A5 true JP2017509694A5 (enExample) | 2018-03-22 |
| JP6723930B2 JP6723930B2 (ja) | 2020-07-15 |
Family
ID=50241356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016568146A Active JP6723930B2 (ja) | 2014-02-07 | 2015-02-09 | シグマ−１−受容体アゴニスト化合物の新規使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10124006B2 (enExample) |
| EP (1) | EP3104847B8 (enExample) |
| JP (1) | JP6723930B2 (enExample) |
| CN (1) | CN106456578B (enExample) |
| CA (1) | CA2938928C (enExample) |
| DK (1) | DK3104847T3 (enExample) |
| ES (1) | ES2848710T3 (enExample) |
| HR (1) | HRP20210114T1 (enExample) |
| HU (1) | HUE053165T2 (enExample) |
| IL (1) | IL247143B (enExample) |
| PL (1) | PL3104847T3 (enExample) |
| SI (1) | SI3104847T1 (enExample) |
| WO (1) | WO2015118365A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2700448R1 (es) * | 2016-06-07 | 2019-02-26 | Esteve Pharmaceuticals Sa | Uso de ligandos del receptor sigma en la diabetes y el sindrome metabolico |
| ES2926179T3 (es) * | 2016-11-24 | 2022-10-24 | Sigmadrugs Kutato Korlatolt Feleloessegue Tarsasag | Utilización de composiciones para la conservación de órganos/tejidos |
| CN111386110B (zh) * | 2017-10-20 | 2024-02-20 | 阿纳韦克斯生命科学公司 | 心脏功能障碍的治疗 |
| WO2020123847A1 (en) * | 2018-12-12 | 2020-06-18 | Rutgers, The State University Of New Jersey | Organic compounds |
| US20220117951A1 (en) * | 2019-02-14 | 2022-04-21 | Algernon Pharmaceuticals Inc. | Compositions and methods for treating idiopathic pulmonary fibrosis |
| WO2021081624A1 (en) | 2019-10-28 | 2021-05-06 | Algernon Pharmaceuticals Inc. | Use of glutamate 2b receptor antagonists and sigma receptor agonsists as antitussives |
| CN112386679B (zh) * | 2020-11-18 | 2023-05-30 | 徐州医科大学 | 一种包载sigma-1受体的外泌体在制备抗抑郁药物中的应用 |
| US20230263797A1 (en) * | 2021-08-26 | 2023-08-24 | Unm Rainforest Innovations | Mammalian Hybrid Pre-Autophagosomal Structure HyPAS and Compositions and Methods for the Treatment of Coronavirus Infections and Related Disease States |
| WO2024094156A1 (zh) * | 2022-11-04 | 2024-05-10 | 石药集团中奇制药技术（石家庄）有限公司 | 胺类化合物及其用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7503310A (nl) | 1975-03-20 | 1976-09-22 | Philips Nv | Verbindingen met antidepressieve werking. |
| IN186677B (enExample) | 1999-11-12 | 2001-10-20 | Sun Pharmaceutical Ind Ltd | |
| HUP0201284A3 (en) | 2000-02-22 | 2003-02-28 | Daiichi Asubio Pharma Co Ltd | Preventive or therapeutic drugs for fibrosis containing quinazolindione derivative chymase inhibitors as the active ingredient |
| JP4459621B2 (ja) * | 2001-11-13 | 2010-04-28 | シェーリング コーポレイション | Ｎｋ１アンタゴニスト |
| AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
| AU2003257666A1 (en) | 2002-08-23 | 2004-03-11 | Kirin Beer Kabushiki Kaisha | COMPOUND HAVING TGFss INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME |
| GB0715047D0 (en) | 2007-08-02 | 2007-09-12 | Glaxo Group Ltd | Novel Compounds |
| DE102007063535A1 (de) * | 2007-12-21 | 2009-06-25 | Cycnad Gmbh & Co. Kg | Pharmazeutische Zusammensetzung zur Prophylaxe und/oder symptomatischen Behandlung von zystischer Fibrose |
| CA2741954A1 (en) | 2008-10-29 | 2010-05-06 | Pacific Therapeutics Ltd. | Composition and method for treating fibrosis |
| WO2010085959A1 (en) | 2009-01-28 | 2010-08-05 | Aarhus Universitet | Treatment of radiation-induced fibrosis |
| EP2353598A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for use in the prevention and/or treatment of postoperative pain |
| WO2011146863A1 (en) * | 2010-05-21 | 2011-11-24 | Alcon Research, Ltd. | Surgical compositions containing sigma-receptor agonists |
| JP6069356B2 (ja) | 2012-01-05 | 2017-02-01 | クラノテク・アクチボラグ | 線維症又は線維症関連疾患の治療に使用するための、抗血管新生性のインテグリンα５β１阻害剤であるキノリン化合物 |
-
2015
- 2015-02-09 JP JP2016568146A patent/JP6723930B2/ja active Active
- 2015-02-09 CN CN201580018235.6A patent/CN106456578B/zh active Active
- 2015-02-09 CA CA2938928A patent/CA2938928C/en active Active
- 2015-02-09 WO PCT/HU2015/000014 patent/WO2015118365A1/en not_active Ceased
- 2015-02-09 SI SI201531492T patent/SI3104847T1/sl unknown
- 2015-02-09 PL PL15715809T patent/PL3104847T3/pl unknown
- 2015-02-09 HU HUE15715809A patent/HUE053165T2/hu unknown
- 2015-02-09 ES ES15715809T patent/ES2848710T3/es active Active
- 2015-02-09 EP EP15715809.8A patent/EP3104847B8/en active Active
- 2015-02-09 DK DK15715809.8T patent/DK3104847T3/da active
- 2015-02-09 US US15/117,233 patent/US10124006B2/en active Active
- 2015-02-09 HR HRP20210114TT patent/HRP20210114T1/hr unknown
-
2016
- 2016-08-07 IL IL24714316A patent/IL247143B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017509694A5 (enExample) | ||
| RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| HRP20210114T1 (hr) | Nova primjena spoja agonista sigma-1 receptora | |
| RU2459811C2 (ru) | Ингибиторы гистоновой деацетилазы | |
| JP2019537605A5 (enExample) | ||
| RU2009148673A (ru) | Производные пиразинона и их применение для лечения легочных заболеваний | |
| RU2012158142A (ru) | Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации | |
| RU2017145930A (ru) | МОДУЛЯТОРЫ ROR ГАММА (RORγ) | |
| RU2008112184A (ru) | Производное тиазола | |
| JP2014502979A5 (enExample) | ||
| RU2014115427A (ru) | Фармацевтические композиции замещенных хиназолинонов | |
| RU2004104625A (ru) | Аналоги простагландинов в качестве агонистов рецептора ep4 | |
| RU2013155586A (ru) | [1,3]оксазины | |
| JP2019501130A5 (enExample) | ||
| RU2011146363A (ru) | Производные n-ацил-n-фенилпиперазина, используемые (кроме того) для профилактики или лечения диабета | |
| JP2005536475A5 (enExample) | ||
| JP2007502806A5 (enExample) | ||
| JP2019507179A5 (enExample) | ||
| RU2019136279A (ru) | C5 -Анилинохиназолиновые соединения и их использование в лечении рака | |
| CN107635975B (zh) | Dgat2抑制剂 | |
| RU2010134411A (ru) | Фенилацетамидное производное | |
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| RU2008143232A (ru) | Новый класс ингибиторов гистондеацетилаз | |
| RU2013130879A (ru) | Производные оксазолилметилового эфира в качестве агонистов рецептора alx | |
| RU2015142383A (ru) | Новейшие антагонисты trpa1-рецепторов |